MicroRNA Profiles in Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups. There is no targeted therapy unlike other types of breast cancer such as hormone positive and Human Epidermal Growth factor 2 (HER2) positive subtypes. Chemotherapy is therefore the main choice of systemic treatment with rapid development of resistance in most cases. At present, there is no blood test to monitor treatment response and disease relapse. This one-stage phase II study with a single arm design will determine the response rate of standard chemotherapy us

Trial Details

NCT ID

NCT04771871

Phase

PHASE2

Sponsor

University College Hospital, Ibadan

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Epirubicin
Cyclophosphamide
Paclitaxel
Carboplatin

Locations (sample)

Ile-Ife, Oshun, Nigeria|7.4824,4.56032
Ibadan, Oyo State, Nigeria|7.37756,3.90591
Lagos, Nigeria|6.45407,3.39467
Lagos, Nigeria|6.45407,3.39467

Key Eligibility Criteria

Women ages of 18 to 70 years old
Women who give informed consent for the study
Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm)
Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →